Unknown

Dataset Information

0

Long-term survival and polyclonal immunoglobulin reconstitution after allogeneic stem cell transplantation in multiple myeloma.


ABSTRACT: Despite significant progress made in the treatment of patients with multiple myeloma (MM) in the last decade, for patients with early relapse or rapidly progressing high-risk disease, allogeneic hematopoietic stem cell transplantation (SCT) might be an option leading to long-term survival. Here, we retrospectively analyzed the outcomes of 90 MM patients who received allogeneic SCT in our center between 1999 and 2017. We specifically assessed the association of impaired humoral immune reconstitution, referred to as immunoparesis, and post-transplant survival. Sixty-four patients received allogeneic SCT in relapse following 2-7 lines of therapy; 26 patients received upfront tandem autologous-allogeneic SCT. With a median follow-up of 76 months, OS and PFS were 52.6% (95% CI 42.9-64.3) and 36.4% (95% CI 27.6-47.9) at 2 years and 38.6% (95% CI 29.2-51.1) and 25.3% (95% CI 17.5-36.4) at 5 years, respectively. Receiving more than two therapy lines prior to transplantation was an independent risk factor for OS (HR 3.68, 95% CI 2.02-6.70) and PFS (HR 3.69, 95% CI 2.09-6.50). In a landmark analysis at day 200, prolonged immunoparesis was associated with reduced OS (HR 3.22, 95% CI 1.14-9.11). Allogeneic stem cell transplantation offers an additional treatment element that may lead to long-term remission in selected patients with poor prognosis, probably exploiting graft-versus-myeloma effects. Immunoparesis could potentially serve as an indicator for impaired survival following allogeneic transplantation, an observation to be further studied prospectively.

SUBMITTER: Eisfeld C 

PROVIDER: S-EPMC7340674 | biostudies-literature | 2020 Aug

REPOSITORIES: biostudies-literature

altmetric image

Publications

Long-term survival and polyclonal immunoglobulin reconstitution after allogeneic stem cell transplantation in multiple myeloma.

Eisfeld Christine C   Eßeling Eva E   Wullenkord Ramona R   Khandanpour Cyrus C   Reusch Julia J   Mikesch Jan-Henrik JH   Reicherts Christian C   Kerkhoff Andrea A   Schliemann Christoph C   Kessler Torsten T   Mesters Rolf M RM   Berdel Wolfgang E WE   Lenz Georg G   Stelljes Matthias M  

Annals of hematology 20200522 8


Despite significant progress made in the treatment of patients with multiple myeloma (MM) in the last decade, for patients with early relapse or rapidly progressing high-risk disease, allogeneic hematopoietic stem cell transplantation (SCT) might be an option leading to long-term survival. Here, we retrospectively analyzed the outcomes of 90 MM patients who received allogeneic SCT in our center between 1999 and 2017. We specifically assessed the association of impaired humoral immune reconstitut  ...[more]

Similar Datasets

| S-EPMC5826888 | biostudies-literature
| S-EPMC6355483 | biostudies-literature
| S-EPMC5477611 | biostudies-literature
| S-EPMC6355495 | biostudies-literature
| S-EPMC3542410 | biostudies-literature
| S-EPMC3107742 | biostudies-literature
| S-EPMC6988393 | biostudies-literature
| S-EPMC7483973 | biostudies-literature
| S-EPMC2665904 | biostudies-other
| S-EPMC5036168 | biostudies-literature